Last edition
News about "Chugai Pharmaceutical "
Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD
Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.
Chugai Pharmaceutical | 25/03/2026 | By News Bureau | 167
Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.
Chugai Pharmaceutical | 24/03/2026 | By News Bureau | 106
Chugai Launches Elevidys Gene Therapy for Duchenne Muscular Dystrophy in Japan
Elevidys receives conditional approval and NHI listing for ambulatory DMD patients aged three to under eight years; launch backed by Phase III EMBARK study and strengthened safety measures.
Chugai Pharmaceutical | 23/02/2026 | By News Bureau | 177
Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia
Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.
Chugai Pharmaceutical | 24/10/2025 | By Dineshwori | 527
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy